New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For NVO;VPHM;INFI;MRK;AGN;SHPG;SGEN;OREX;AMGN;SNY;JNJ;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>
October 27, 2014
16:06 EDTAMGNAmgen raises FY14 EPS view to $8.45-$8.55 from $8.20-$8.40, consensus $8.42
Raises FY14 revenue view to $19.8B-$20B from prior view $19.5B-$19.7B, consensus $19.73B.
16:04 EDTAMGNAmgen reports Q3 EPS $2.30, consensus $2.11
Subscribe for More Information
15:36 EDTPFENotable companies reporting before tomorrow's open
Subscribe for More Information
15:34 EDTAMGNNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Amgen (AMGN), consensus $2.11; General Growth Properties (GGP), consensus 31c; Avalonbay (AVB), consensus $2.00; Hartford Financial (HIG), consensus 83c; Universal Health Services (UHS), consensus $1.36; XL Group (XL), consensus 63c; Masco (MAS), consensus 32c; Plum Creek Timber (PCL), consensus 30c; T-Mobile US (TMUS), consensus 2c; Cliffs Natural (CLF), consensus (3c); Twitter (TWTR), consensus 1c; American Capital Agency (AGNC), consensus 73c; DDR Corp. (DDR), consensus 30c; PartnerRe (PRE), consensus $3.66; Owens & Minor (OMI), consensus 47c; Manitowoc (MTW), consensus 42c; Compass Minerals (CMP), consensus 78c; Allison Transmission (ALSN), consensus 30c; Regal Entertainment (RGC), consensus 17c.
15:18 EDTPFEEarnings Preview: Pfizer looks to new products to offset generic competition
Subscribe for More Information
14:49 EDTAMGNEarnings Preview: Amgen Q3 results may be driven by Enbrel, Kyprolis, Prolia
Subscribe for More Information
12:46 EDTPFEPfizer October weekly volatility elevated into Q3 and outlook
Subscribe for More Information
10:52 EDTSGENSeattle Genetics, Aegerion CEOs accused of drug use in lawsuit, TheStreet says
Subscribe for More Information
10:36 EDTSHPG, AGNAllergan delivers earnings beat, says willing to consider higher Valeant bid
Subscribe for More Information
10:13 EDTAGNAllergan backs view for double digit revenue growth rate FY14-FY19
Subscribe for More Information
10:12 EDTAGNAllergan repeats FY15, FY16 guidance
Subscribe for More Information
10:09 EDTAMGNAmgen volatility elevated into Q3 and outlook
Subscribe for More Information
09:50 EDTAGNAllergan CEO says cannot respond to market rumors about potential targets
Subscribe for More Information
09:42 EDTAGNAllergan says Valeant announcement not raised bid, really 'offer to negotiate'
Allergan (AGN) CEO David Pyott says Valeant's (VRX) announcement today is really "an offer to negotiate," not a true increased bid.
09:37 EDTMRKMerck slips lower after results, levels to watch
Subscribe for More Information
09:34 EDTAGNAllergan says if pursues acquisition, would need to be announced by early Dec.
Allergan says that if it pursues an acquisition, the transaction would likely need to be announced by "early December." Allergan CEO David Pyott also noted that some shareholders have urged the company to pursue a stock buyback if it does not find a suitable acquisition target that it chooses to pursue.
09:30 EDTAGNAllergan says many stockholders privately supportive of deploying balance sheet
Subscribe for More Information
09:14 EDTAGNOn The Fly: Pre-market Movers
Subscribe for More Information
09:12 EDTAGNAllergan says Valeant offers 'grossly inadequate'
Allergan (AGN) issued the following statement in response to Valeant's (VRX) October 27 letter to the Allergan board. The company said, "Delivering value to Allerganís stockholders remains the Boardís highest priority. If Valeant were to make an increased offer, the Board would carefully consider it and respond in due course. However, to date, as we have noted repeatedly, Valeantís offers have been grossly inadequate and significantly undervalued Allergan. We believe Valeant's letter today is simply a tactic to distract investors from Allergan's outstanding third quarter results. Valeantís letter does not indicate an increased exchange offer price nor does it disclose the mix of consideration, instead, Valeant goes to great lengths to defend its own stock price and to disparage Allergan, including making what we believe to be disparaging remarks about Allergan and its stock price. The Allergan board has taken a number of actions over the past six months that have delivered tangible value to our stockholders and will continue to do so in the future. Wall Street analysts have recognized these actions and significantly raised the floor for a standalone Allergan. Allergan believes that any assertion that Allerganís stock would be trading near its first quarter trading price absent the Valeant offer is not substantiated by fact. We also note that a number of long Allergan stockholders that have decreased their Allergan positions have told Allergan that they did so as they do not want to own Valeant stock."
09:11 EDTAGNAllergan says Valeant offers 'grossly inadequate'
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use